Table 2.
Summary of the studies in human tumors using scRNAseq.
| Cancer type | Tumor cell types | scRNAseq method | Cell number | References |
|---|---|---|---|---|
| Glioblastoma | Cancer epithelial cells | Smart-seq | 430 | (150) |
| Oligodendrogliomas | Cancer epithelial cells | Smart-seq2 | 4,347 | (151) |
| Hepatocellular cancer | Cancer epithelial cells | scTrio-seq | 25 | (152) |
| Renal carcinoma | PDX | Fluidigm C1/SMARTer | 116 | (153) |
| Lung adenocarcinoma | PDX | Smart-seq | 34 | (154) |
| Chronic myeloid leukemia | Lin−CD34+CD38− cells | BCR-ABL-targeted Smart-seq2 | 2,000 | (155) |
| Breast cancer (TNBC) | Cancer epithelial cells | Nanogrid single-nucleus RNA seq | 7,278 | (148, 156) |
| Hepatocellular cancer | CD8+ and CD4+ T cells | Smart-seq2 | 5,063 | (113) |
| Gliomas | Inter (CD11b+) and Intra tumor TAMs (in silico) | 10X Genomics | 4,039 | (157) |
| Gliomas | Inter (CD11b+) and Intra tumor TAMs (in silico) | Fluidigm C1/SMARTer | 466 | (157) |
| Non-small-cell lung cancer | CD3+ TILs | Smart-seq2 | 12,346 | (115) |
| Breast cancer (TNBC) | CD3+ TILs | 10X Genomics Chromium | 6,311 | (117) |
| Breast cancer (ER+PR+, Her2+, TNBC) | Immune cells (CD45+) | inDrop | 47,016 | (114) |
| Breast cancer (ER+PR+, Her2+, TNBC) | CD3+ TILs | 10X Genomics Chromium (scRNA-seq and paired V(D)J sequencing) | 27,000 | (114) |
| Melanoma | All cell types in tumor | Smart-seq2 | 4,645 | (112) |
| Head and neck cancer | All cell types in tumor | Smart-seq2 | 5,902 | (158) |
| Breast cancer(ER+PR+, Her2+, TNBC) | All cell types in tumor | Fluidigm C1/SMARTer | 515 | (111) |
| Colorectal cancer | All cell types in tumor | Fluidigm C1/SMARTer | 590 | (159) |
| Non-small-cell lung cancer | All cell types in tumor | 10X Genomics Chromium | 92,948 | (116) |